KNSA - Company ID 0001730430
The table below shows Kiniksa Pharmaceuticals, Ltd.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M | - |
| Cost of revenue | $77.67M | $60.91M | $33.41M | $22.89M | $9.10M | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $96.85M | $111.62M | $76.10M | $65.49M | $99.30M | $112.04M |
| SG&A |
Kiniksa Pharmaceuticals, Ltd. reported annual revenue of $677.56M for fiscal year 2025. That is up 60.1% from $423.24M in fiscal 2024. Over the 5 fiscal years shown, annual revenue grew from $38.54M (FY 2021) to $677.56M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $196.27M |
| $168.01M |
| $129.43M |
| $97.95M |
| $85.95M |
| $45.32M |
| Operating income | $77.22M | -$45.62M | -$25.20M | $9.77M | -$156.64M | -$157.36M |
| Income tax | $29.86M | $7.04M | -$30.74M | -$172.34M | $1.39M | $5.15M |
| Net income | $59.01M | -$43.19M | $14.08M | $183.36M | -$157.92M | -$161.38M |
| EPS (diluted) | $0.75 | -$0.60 | $0.20 | $2.60 | -$2.30 | -$2.61 |